No connection

Search Results

ALGS vs RNXT

ALGS
Aligos Therapeutics, Inc.
BEARISH
Price
$7.57
Market Cap
$46.6M
Sector
Healthcare
AI Confidence
85%
RNXT
RenovoRx, Inc.
BEARISH
Price
$1.00
Market Cap
$45.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ALGS
--
RNXT
--
Forward P/E
ALGS
-1.42
RNXT
-8.33
P/B Ratio
ALGS
0.87
RNXT
6.76
P/S Ratio
ALGS
21.31
RNXT
40.12
EV/EBITDA
ALGS
0.3
RNXT
-3.19

Profitability

Gross Margin
ALGS
0.0%
RNXT
70.88%
Operating Margin
ALGS
-12907.7%
RNXT
-1269.75%
Profit Margin
ALGS
0.0%
RNXT
0.0%
ROE
ALGS
-196.91%
RNXT
-225.62%
ROA
ALGS
-69.33%
RNXT
-92.59%

Growth

Revenue Growth
ALGS
-73.1%
RNXT
453.5%
Earnings Growth
ALGS
--
RNXT
--

Financial Health

Debt/Equity
ALGS
0.1
RNXT
0.04
Current Ratio
ALGS
3.9
RNXT
4.02
Quick Ratio
ALGS
3.67
RNXT
3.65

Dividends

Dividend Yield
ALGS
--
RNXT
--
Payout Ratio
ALGS
0.0%
RNXT
0.0%

AI Verdict

ALGS BEARISH

ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.

Strengths
Analyst consensus is strongly bullish with a $80.25 target price
Recent quarterly EPS growth shows strong momentum (+85.4% YoY, +37.2% Q/Q)
Positive earnings surprises in 2 of the last 4 quarters (average +3.87%)
Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative operating margin (-12,907.69%) and ROE (-196.91%) reflect deep unprofitability
73.1% YoY revenue decline indicates business contraction
RNXT BEARISH

RNXT exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.02 and very low debt, it is burning cash at an unsustainable rate with an operating margin of -1269.75%. The valuation is disconnected from fundamentals, trading at a Price/Sales ratio of 40.12. Despite aggressive 'strong buy' analyst targets of $6.88, the deterministic data suggests a high-risk speculative profile with a long-term bearish price trend.

Strengths
Strong short-term liquidity (Current Ratio: 4.02)
Very low leverage (Debt/Equity: 0.04)
Explosive year-over-year revenue growth (453.50%)
Risks
Extreme operational inefficiency (Operating Margin: -1269.75%)
Severe fundamental health failure (Piotroski F-Score: 1/9)
Extreme valuation premium (Price/Sales: 40.12)

Compare Another Pair

ALGS vs RNXT: Head-to-Head Comparison

This page compares Aligos Therapeutics, Inc. (ALGS) and RenovoRx, Inc. (RNXT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile